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Natural killer (NK) cells play a central role in host defense against
various pathogens. Functional defects of NK cells in HIV-1 infection as
a direct effect of abnormal expression or function of inhibitory NK
receptors (iNKRs), activating natural cytotoxicity receptors (NCRs),
and NKG2D have not yet been described. This study demonstrates an
expansion of the functionally defective CD56CD16 population of
NK cells in viremic versus aviremic patients. We also demonstrate that
in HIV-infected viremic patients, expression of iNKRs was well con-
served and that in most cases, there was a trend toward increased
expression on NK cells as compared with healthy donors. It was also
demonstrated that the major activating NK receptors, with the ex-
ception of NKG2D, were significantly down-regulated. In contrast, the
expression of iNKRs and activating receptors in HIV-infected individ-
uals whose viremia was suppressed to below detectable levels by
highly active antiretroviral therapy for 2 years or longer was compa-
rable to that of healthy donors. Functional tests confirmed that the
abnormal expression of the activating receptors and of iNKRs was
associated with a markedly impaired NK cytolytic function. This
phenomenon is not attributed to a direct HIV-1 infection of NK cells;
thus, this study may provide insight into the mechanisms of impaired
host defenses in HIV-1 viremic patients.
Natural killer (NK) cells are an important component of theinnate immune system. They are characterized by the lack of
expression of conventional receptors for antigen, such as surface Ig
or T cell receptor (TCR); however, they are able to distinguish
between normal MHC class I (MHC-I)-positive cells and cells that
have lost their expression as a consequence of tumor transforma-
tion or viral infection (1). A delicate balance between opposite
signals delivered by the MHC-I-specific inhibitory NK receptors
(iNKRs) and by the activating receptors, referred to as natural
cytotoxicity receptors (NCRs) and NKG2D, regulates NK cell
cytotoxicity. Under normal conditions, the iNKRs are dominant
over the NCRs and NKG2D (2, 3). In humans, the iNKRs expressed
on NK cells are divided into different groups: (i) killer Ig-like
receptors (KIRs) that recognize different allelic groups of classical
human leukocyte antigens of class I (HLA-A, -B, and -C); (ii)
LIR1ILT2 that binds HLA-A, -B, -C, and -G; and (iii) NKG2A
CD94 that binds nonclassical HLA-E and belongs to the family of
the C-type lectin proteins (3, 4). Certain surface receptors that
trigger NK cell killing have recently been identified and labeled as
NCRs. They include NKp46, NKp30, and NKp44; the first two are
constitutively expressed only on resting and activated NK cells,
whereas NKp44 is only present on activated cells (3). Very little is
known about the ligands of these NCRs; it has been suggested that
they can be expressed on cells ‘‘stressed’’ by viral infection or tumor
transformation (5). Another important activating receptor is
NKG2D, also expressed on a subset of cytolytic T lymphocytes, for
which the ligands have been designated (6). There are also core-
ceptors, including 2B4, NKp80, and NTBA, that work synergisti-
cally with NCRs in driving NK cytotoxicity (3, 5). Understanding
the balance between inhibitory and activating molecules expressed
on NK cells has allowed us to understand the mechanism by which
NK cells are able to eliminate tumor or virus-infected cells that
either lack or down-regulate their self-MHC-I molecules.
Various aspects of NK cell function have been analyzed during
HIV infection. In this regard, NK cells of HIV-infected individuals
have been demonstrated to be an important source of CC-
chemokines, such as RANTES and macrophage inflammatory
proteins 1 and 1, that potently suppress replication of R5 strains
of HIV (7, 8). Furthermore, there is an inverse correlation between
the level of plasma viremia and the ability of NK cells and NK
cell-derived supernatants to suppress endogenous HIV replication
in CD4 T cells ex vivo (9). It has also been reported that the
CD56dimCD16 NK subset is decreased in HIV-infected individ-
uals, whereas the CD56bright population is conserved (10). More-
over, the CD56CD16 subset of NK cells, which is present in an
extremely low percentage in uninfected individuals, is common in
HIV-1-seropositive subjects (11).
In this study, we performed a phenotypic and functional evalu-
ation of NK cells in viremic patients and in patients whose viremia
had been suppressed to below detectable levels with highly active
antiretroviral therapy (HAART). We find a striking perturbation
of the differential expression of iNKRs and activating receptors on
NK cells of viremic compared with aviremic patients that correlates
with clear-cut abnormalities in the function of these cells.
Methods
Study Subjects. Two cohorts of 17 viremic patients and 16 aviremic
HIV-infected patients were studied (Table 1). The viremic group
was composed of 6 patients who were naı¨ve for treatment and 11
who had formerly been receiving HAART but whose treatment
regimen had been discontinued. Within the group of the six
treatment-naı¨ve viremic patients, none were experiencing primary
HIV-1 infection. No difference in terms of the expression and
function of NK receptors was found between treated and untreated
viremic patients. The aviremic group had been receiving HAART
continually for at least 24 months, and all 16 aviremic patients
included in this cohort had initiated HAART early in the course of
infection before the establishment of chronic HIV-1 infection.
Peripheral blood mononuclear cells (PBMCs) were obtained by
apheresis, and all patients were enrolled in specific protocols
approved by the National Institute of Allergy and Infectious
Diseases Institutional Review Board. As negative controls, we used
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PBMCs from 13 healthy donors seronegative for HIV-1 (Table 1)
that were obtained by apheresis generously provided by the Trans-
fusion Medicine Department of the National Institutes of Health
Clinical Center. There were no statistical differences among the
three groups of study subjects in the median number and percent
of NK cells in peripheral blood, and the number of CD4 T cells
was never below 200mm3 in any HIV-infected subject.
Isolation and Culture of NK Cells. To obtain peripheral blood
lymphocytes (PBLs), PBMCs were isolated over Ficoll–Hypaque
gradients (LSM, ICN). Enrichment of NK cells from PBLs was
performed by using column-based cell separation techniques
(StemCell Technologies, Vancouver) as described (9–12). The
purity of NK cells was 97%. To activate freshly isolated NK cells,
we cultured them for 6 days in 96-well round-bottom plates at a
concentration of 106 cells per ml with RPMI medium 1641 sup-
plemented with penicillinstreptomycin, L-glutamine (GIBCO),
10% FCS (HyClone), and recombinant IL-2 (rIL-2; Roche Molec-
ular Biochemicals) at 200 unitsml.
Monoclonal Antibodies. The following mAbs were provided by A.M.
and D. Pende (University of Genoa): 289 (IgG2a anti-CD3), C218
and FS280 (IgG1 and IgG2a anti-CD56, respectively), KD1 (IgG2a
anti-CD16), Gl183 (IgG1 anti-p58.2), 11pb6 (IgG1 anti-p58.1), Z27
(IgG1 anti-p70), F278 (IgG1 anti-LIR1ILT2), Z270 (IgG1 anti-
NKG2A), Xa185 (IgG1 anti-CD94), Bab 281 and KL247 (IgG1 and
IgM anti-NKp46, respectively), Az20 and F252 (IgG1 and IgM
anti-NKp44, respectively), Z231 (IgG1 anti-NKp44), On72 and
Bat221 (IgG1 anti-NKG2D), pp35 (IgG1 anti-2B4), Ma152 (IgG1
anti-NKp80), and Ma127 (IgG1 anti-NTB-A). Anti-CD4 (IgG1),
anti-TCR (IgG1), anti-TCR (IgG1), anti-CD19 (IgG1),
and anti-CD14 (IgG1) were purchased from Becton Dickinson.
Flow Cytometric Analysis and Cytolytic Activity. For one- or two-
color cytofluorometric analysis (FACSCalibur, Becton Dickinson),
freshly isolated and rIL2-activated NK cells were stained with the
appropriate mAbs followed by phycoerythrin (PE)- or FITC-
conjugated isotype-specific goat anti-mouse second reagent (South-
ern Biotechnology Associates and IDLabs, London, ON, Canada).
Second appropriate anti-isotypic mAbs conjugated with PE andor
FITC were used as negative controls. After 6 days of activation with
rIL2, NK cells were tested for cytolytic activity in a 4-h 51Cr release
assay as described (13). The different effectortarget (ET) ratios
are indicated in the figures. The saturating concentrations of the
various mAbs added were 0.5 gml for redirected killing assay
performed with FcR P815 target cell lines.
Detection of HIV-1 DNA by Real-Time PCR. HIV DNA was quantitated
as described (14) and adapted for real-time PCR technology.
Briefly, genomic DNA was extracted from fresh or frozen PBMCs
or NK cells by using the Puregene DNA extraction kit (Gentra
Systems). One microgram of genomic DNA was amplified in
triplicate by using primers and a probe specific for the RU5 region
of the HIV-1 5 LTR. Because these primers target a highly
conserved region of HIV-1, viral DNA can be detected during the
early stages of virus replication and as integrated proviral DNA.
The primer sequences are as follows: RU5–5, 5-GGTCTCTCT-
GGTTAGACCAGAT-3; RU5–3, 5-CTGCTAGAGATTTTC-
CACACTG-3; and RU5 probe, 5-FAM-AGTAGTGTGTGC-
CCGTCTAGG-TAMRA-3. PCR cycling conditions with the 7700
SDS (Applied Biosystems) include a 94°C denaturation for 2 min
followed by 45 cycles of 94°C for 15 sec and 58°C for 1 min. A
standard curve derived from limiting dilutions of ACH2 genomic
DNA was used to quantitate HIV copy numbers. Values are given
as the average HIV-1 copy per microgram of DNA. The lowest limit
of detection was 10 copies per microgram of DNA.
IFN- and Transforming Growth Factor  (TGF-) Detection. Culture
supernatants from NK cells were tested after 6 h (freshly isolated
cells) and 6 days (IL-2-activated cells) for levels of IFN- and
TGF- secretion by ELISA (R & D Systems).
Statistical Analysis. The medians and distributions for each variable
of the three cohorts were compared by using the Kruskal–Wallis
test with the Wilcoxon two-sample test. The Bonferroni method
was used to adjust P values for multiple testing.
Results
Phenotypic and Functional Analyses of NK Cells Derived from HIV-1-
Positive Viremic or HAART-Treated Aviremic Patients. Freshly drawn
NK cell populations, purified from purified blood lymphocytes of
both cohorts of HIV-infected individuals and healthy donors were
negative for CD3, CD4, TCR, TCR, CD19, and CD14, and
were analyzed by double cytofluorometric analysis for the expres-
sion of the CD56 and CD16 cell surface markers (Fig. 1 A and B).
In the cohort of viremic patients, the CD56dimCD16 subset was
sharply decreased as compared with NK cells derived from healthy
donors. Of note is that in these viremic individuals, a large subset
of cells (20–55% of the total NK cells) manifested the CD56
CD16 phenotype, which is rare in normal individuals (P  0.05).
In contrast, aviremic HIV-infected individuals treated with
HAART for 2 years displayed a NK cell surface phenotype
similar to that of normal individuals (P  0.05). Indeed, the
majority of NK cells in aviremic patients were CD56CD16,
whereas only a minor subset was characterized by the CD56
CD16 phenotype. In all groups of individuals, the population
characterized by the CD56brightCD16 phenotype was well rep-
resented (6–9% of the total NK cells) in freshly isolated NK cells,
and no significant differences were noted within the three cohorts
in either fresh-by-isolation or IL-2-activated NK cells. Cell surface
distribution of CD56 versus CD16 was also analyzed in NK cells
cultured in the presence of rIL-2. After 6 days of culture, NK cells
derived from normal donors and from both cohorts of HIV-
infected individuals expressed the early activation marker CD69
(data not shown). Interestingly, although the CD56 surface density
increased once cells were activated, the CD56CD16 subset still
represented a high proportion of the NK cells in HIV-infected
viremic patients (15–45%) (P  0.05) (Fig. 1 A and B).
rIL-2-activated NK cells from both cohorts of HIV-infected
individuals were analyzed for cytolytic activity against the NK-
susceptible K562 erythroleukemia cell line. As shown in Fig. 1C, the
mean cytolytic activity of NK cells from HAART-treated aviremic
patients was only slightly reduced as compared with that of normal
controls. In contrast, the ability to kill K562 target cells was clearly
reduced in NK cells from viremic patients at all ET ratios used
(P  0.05).
Table 1. Profile of viremic and aviremic HIV-infected patients
and healthy donors
Group* n
Viral load,
copies RNA per ml†
NK cells,
%‡
CD4
cellsl
Viremic patients 17 32,831  44,447 9 556  247
Aviremic patients HAART 16 50 8.5 520  287
Healthy donors 13 — 11 1,455  293
Results are presented as mean  SD or median for NK cells.
*Highly active antiretroviral therapy (HAART) included at least one protease
inhibitor andor two nucleoside reverse-transcriptase inhibitors and one
nonnucleoside reverse-transcriptase inhibitor.
†Plasma viremia was analyzed by an ultrasensitive bDNA assay with a lower
limit detection of 50 copies per ml of plasma.
‡NK cells are expressed as median percent of total lymphocytes derived from
PBMCs.
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Surface Expression and Function of HLA Class I-Specific NK Cell
Receptors in NK Cells from HIV-Infected Individuals. In our study, we
evaluated the surface expression of different iNKRs specific for
classical or nonclassical HLA class I molecules. These included
KIRs such as KIR2DL2p58.2, KIR2DL1p58.1, KIR3DL1p70
(specific for HLA-C 1, 3, 7, and 8, HLA-C 2, 4, 5, and 6 and
HLA-Bw4, respectively), LIR1ILT2 (recognizing HLA-A, -B, -C,
and -G) and the CD94NKG2A heterodimer specific for HLA-E
(6–8). NKG2A is always coupled with CD94, a molecule that itself
does not bind any MHC and does not trigger any function; however,
it is necessary for surface expression of the NKG2 family, either
inhibitory (NKG2A) or activating (NKG2C) receptors (15). The
expression of the three KIRs examined and LIR1ILT2 on freshly
isolated and IL-2-activated NK cells (Fig. 2) was not only well
conserved in the viremic patients compared with the healthy
donors, but, as a trend, they all showed an increment; within the
viremic cohort the increase for p58.2KIR2DL2 was statistically
significant under both conditions (P  0.05). Of note, in those
patients in whom viremia was suppressed to below detectable levels
by HAART for more than 2 years, the surface patterns of the same
receptors were comparable to those in the cohort of the uninfected
individuals. This phenomenon was not observed with NKG2A,
which showed a statistically significant trend toward decrease in
viremic patients compared with healthy donors (P  0.05). The
levels of CD94 did not parallel the decrease in NKG2A in viremic
patients, and we did not find any difference in the three study
groups (data not shown).
We then analyzed the potential relationship between the expres-
sion of various HLA-specific NK receptors and NK-mediated
cytotoxic function. To this end, NK cells were analyzed in redirected
killing assays against the FcRP815 target cell line in the presence
of anti-CD16 mAb, used alone or in combination with mAb specific
for one or another HLA-specific NK receptors. In this assay, one
would expect that a mAb that would bind to an inhibitory NK
receptor and thus serve as an agonist for that receptor would result
in an inhibition of cytotoxicity that reflected the relative expression
of this inhibitory receptor compared with that of healthy donors. As
shown in Fig. 3, in patients with high HIV-1 viral load, which was
associated with an increased expression of KIR and LIR1ILT2
NK cells, mAb-mediated engagement of one or another KIR or of
LIR1ILT2 resulted in greater inhibition of CD16-induced cyto-
toxicity as compared with normal or aviremic HIV-infected indi-
viduals (P  0.05 for p58.2 and p70). Indeed, the little inhibition
observed in normal individuals is likely attributable to the small
fraction of NK cells expressing one or another KIR, whereas in
HIV-infected patients the incremented inhibitory effects are in line
with the higher percent of NK cells expressing a KIR phenotype.
These data also suggest that the increment in KIR NK cells is
essentially attributable to the expression of inhibitory rather than
Fig. 2. Expression of iNKRs. Graphs show cytofluorometric analyses of
percent of surface expression on freshly isolated (red histograms) and IL-2-
activated (blue lines) NK cells in single representative individuals for 13
healthy donors (Left), 17 viremic patients (Center), and 16 aviremic patients
suppressed by HAART for2 years (Right) of the following iNKRs: p58.2, p58.1,
p70, LIR1ILT2, and NKG2A.
Fig. 1. Phenotypic analysis and functional capability of NK cells. (A) Double
fluorescence cytofluorometric analysis with NK cells stained with CD56 PE
CD16 FITC and characterization of the abnormal CD56CD16 subset in fresh
(red dot plots) and activated (blue dot plots) NK cells with statistical analysis.
This population is markedly represented in HIV-1-positive viremic patients
(open circles) and is very minimally represented in healthy donors and in
HIV-1-positive aviremic individuals. (B) Graphs of statistical dot plots showing
the percentage of the CD56CD16 NK cells subset (freshly isolated, Upper;
activated, Lower) in all of the subjects within the three groups studied with
median (blue bars) and P value between the cohorts of healthy donors versus
viremic patients and viremic versus aviremic patients. HD, healthy donors; VIR,
viremic patients; AVIR, aviremic patients. (C) Spontaneous cytolytic activity of
NK cells activated with rIL-2 in vitro for 6 days against K562 cell lines at
different ET ratios (2:1, 1:1, and 0.5:1) (Lower). Averages were calculated on
13 healthy donors (black squares) versus 17 viremic patients (green circles) and
16 aviremic patients (red diamonds) with statistical analysis (Upper).
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activating KIRs. In line with the decreased expression on NK cells
of viremic patients, NKG2A displayed a reduced capability to
down-regulate the CD16-mediated lysis of target cells.
Both surface expression and function of the KIR3DL2p140
inhibitory receptor (specific for HLA-A3 and -A11), was compa-
rable in both cohorts of HIV-infected individuals and in healthy
donors (data not shown).
Surface Expression and Function of Different Non-HLA-Specific Acti-
vating NK Cell Receptors on NK Cells from HIV-Infected Individuals.
We next analyzed the surface expression of NKG2D and NCRs
NKp46, NKp30, and NKp44. As shown in Fig. 4, cell surface
expression of these markers in both freshly isolated and IL-2-
activated NK cells was comparable in HIV-infected aviremic pa-
tients and in healthy controls. In contrast, in viremic patients the
majority of freshly isolated peripheral blood NK cells displayed the
NKp46dim, NKp30dim phenotype and were characterized by statis-
tically significant decreases in surface densities of these receptors
(P  0.05). Also, the surface expression of the NKp44 molecule
(that is selectively expressed by activated and not resting NK cells)
was decreased in this cohort of patients (P  0.05). Indeed, most
activated NK cells expressed low NKp44 surface densities
(NKp44dim phenotype), whereas only a minor subset expressed
levels of this molecule comparable to that of normal donors. Only
minor differences were detected in NKG2D surface densities
between viremic and aviremic patients (P  0.05).
To evaluate the functional capability of these receptors to induce
NK-mediated cytotoxicity, rIL-2-activated NK cells were analyzed
in redirected killing assays against FcR P815 target cells in the
presence of mAbs specific for one or another activating NK
receptors. In this redirected killing assay, one would expect that a
mAb that would bind to an activating receptor and thus serve as an
agonist for that receptor would result in an increase in cytotoxicity
that reflected the relative expression of this activating receptor
compared with that of healthy donors. No significant differences
could be detected in the triggering capability of all these molecules
in aviremic patients versus normal subjects, thus reflecting the
similarities in expression of these receptors in aviremic patients and
healthy donors. In contrast, in NK cells derived from the viremic
cohort the three NCRs (and to a lesser extent NKG2D) displayed
a clearly reduced ability to enhance NK-mediated cytotoxicity
compared with that of healthy donors, reflecting the decreased
expression of these activating receptors (Fig. 5) (P  0.05 for
NKp46, NKp30, and NKp44; P  0.05 for NKG2D).
Both the expression and function of NKp80, 2B4, and NTB-A,
three coreceptor molecules expressed by NK cells, were compara-
ble in normal donors and in the two cohorts of HIV-infected
patients (data not shown).
PCR Analysis for the Presence of HIV-1 DNA and Secretion of IFN- and
TGF- in NK Cells. It is well known that entry of HIV-1 into its target
cell requires expression of both CD4 and a particular chemokine
Fig. 3. Functional evaluation of iNKRs. Graphs show the functional evalua-
tion of surface expression of the following iNKRs by a redirected killing assay
using an FcR P815 target cell line. The following receptors were evaluated:
p58.2, p58.1, p70, LIR1ILT2, and NKG2A. Data are presented as an average of
all of the data collected from the uninfected individuals (Left), viremic HIV-
infected subjects (Center), and aviremic HIV-infected subjects (Right). ET
ratios are 5:1, 2:1, and 0.5:1. Every graph shows the baseline lysis (open
squares), the maximal lysis triggered by anti-CD16 IgG mAb (open circles), and
the inhibition of killing driven by the relevant inhibitory NK receptors cotrig-
gered with anti-CD16 IgG mAb (filled diamonds).
Fig. 4. Expression of NCRs and NKG2D. Graphs show cytofluorometric
analyses of pattern of surface expression (geometric mean fluorescence) of
NCRs on freshly isolated (red histograms) and IL-2-activated (blue lines) NK
cells in single representative individuals for 13 healthy donors (Left), 17
viremic patients (Center), and 16 aviremic patients suppressed by HAART for
2 years (Right) of the following activating NK receptors: NKp46, NKp30,
NKp44, and NKG2D.
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receptor on the cell surface of potential target cells (16). Because
freshly isolated NK cells do not express CD4 (data not shown), one
would not expect NK cells to become infected with HIV. However,
a recent study reported HIV-1 infection of NK cells (17), and this
prompted us to clarify whether the altered expression of several NK
cell surface receptors could be the result of direct HIV-1 infection
of NK cells. NK cells derived from HIV-infected patients and
healthy donors express the CCR5 andor CXCR4 chemokine
receptors (data not shown), as reported by other groups (18, 19). To
determine whether the NK cell abnormalities observed in our study
were not caused by a direct infection of NK cells by HIV, we
performed PCR analysis on freshly isolated and activated NK cells
derived from HIV-infected patients. To this end, genomic DNA
extracted from PBMCs (as positive control) and from freshly
isolated and activated purified NK cells of the same 14 viremic and
12 aviremic patients was amplified by using primers specific for a
highly conserved region of HIV-1. PBMCs and purified NK cells
from healthy individuals were used as negative controls. Purifica-
tion of NK cells was 97%. In no instance could we detect viral
DNA amplification in NK cells from the viremic and aviremic
patients analyzed (Fig. 6A).
Next we analyzed the production of IFN- and TGF- by NK
cells from both cohorts of HIV-infected patients (Fig. 6B). Freshly
isolated and activated NK cells from healthy donors and from both
viremic and aviremic patients secreted similar amounts of TGF-.
In contrast, a significant reduction in terms of IFN- production
was detected in freshly isolated and activated NK cells from viremic
patients (P  0.05).
Discussion
This study demonstrates that HIV-infected viremic patients man-
ifest perturbations in the differential expression of iNKRs and
activating NK receptors and that these perturbations are associated
with abnormalities in the cytolytic function of these cells. In
contrast, the phenotypic and functional profile of NK cells of
HIV-infected patients who have been rendered aviremic by
HAART for 2 years are similar to those of healthy donors.
There have been a number of reports of abnormalities in NK
cell function in HIV-infected individuals (20, 21). The mecha-
nisms of these dysfunctions are not entirely clear and are most
likely multifactorial. The ability of an NK cell to kill relevant
targets such as virally infected or tumor cells depends on a
delicate balance of the patterns of expression of iNKRs and
activating receptors (4, 5). In recent years several mechanisms
potentially responsible for the regulation of NK cell receptor
expression have been proposed (1, 3, 6); however, a number of
questions remain unanswered related to the ligands of NCRs and
the array of soluble factors that may be involved in the expression
and modulation of the receptors that drive NK cell function. In
this study, we have demonstrated that NK cell cytotoxicity
against K562 target cells was decreased in viremic HIV-infected
individuals compared with that in healthy donors and aviremic
patients. This impaired function has also been observed in the
early stages of HIV infection and in patients with advanced HIV
disease, and the defect progressed over time (11, 22). Two
studies (23, 24) confirmed that freshly isolated NK cells from
HIV-infected individuals had a decreased capacity to kill K562
cells compared with uninfected subjects; however, NK cells from
patients with low or undetectable levels of plasma viremia
surprisingly manifested the least NK cytolytic activity against
K562 (23). A possible explanation for this observation was that
HIV directly stimulated NK cell activity, as has been seen with
other viruses (23), and this phenomenon has also been reported
in vivo in the early stage of simian immunodeficiency virus
infection in rhesus monkeys (25). The reason for this discrepancy
Fig. 5. Functional evaluation of NCRs and NKG2D. Graphs show the func-
tional evaluation of surface expression of the following activating NK recep-
tors by a redirected killing assay using an FcR P815 target cell line: NKp46,
NKp30, NKp44, and NKG2D. Data are presented as an average of all of the data
collected from the uninfected individuals (Left), viremic HIV-infected subjects
(Center), and aviremic HIV-Infected subjects (Right). ET ratios are 5:1, 2:1, and
0.5:1. Every graph shows the baseline lysis (open squares), the maximal lysis
triggered by anti-CD16 IgG-mAb (open circles), and the killing driven by the
relevant activating NK receptors (filled diamonds).
Fig. 6. PCR for HIV-1 DNA and secretion of IFN- and TGF-. (A) Copies per
microgram (mean) with standard deviation of HIV-1 on PBMCs and fresh and
activated purified NK cells in the three cohorts of 9 healthy donors (first
group), 12 aviremic patients (second group), and 14 viremic patients (third
group). (B) Secretion of IFN- (Left) and TGF- (Right) measured in NK cell
culture supernatant after 6 h (freshly isolated NK cells) and 6 days of culture
in rIL-2 (activated NK cells) in healthy donors (open bars), viremic patients
(filled bars), and aviremic patients (stippled bars).
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with our reported results is unclear at present; however, it should
be pointed out that all these data were obtained by using freshly
isolated, unfractionated PBMCs, and purified NK cells were not
used to evaluate cytolytic function. In contrast, our functional
experiments were performed after culturing purified NK cells
for 6 days in the absence of virus and in the presence of rIL-2.
In this way, we were able to measure the true capacity of purified
NK cells, when stimulated by a classical cytokine, to trigger
killing of NK-sensitive targets such as K562. Of note is that
spontaneous lysis of K562 cells by NK cells was abnormally low
in viremic patients, and the abnormal population of CD56
CD16 NK cells was highly represented in viremic patients but
was not seen in HIV-infected patients whose viremia was
suppressed by HAART or in healthy donors.
We sought to determine whether a correlation existed between
abnormal phenotype of NK cells and cytolytic dysfunction. The
redirected killing assay clearly demonstrated that the KIRs ana-
lyzed and LIR1ILT2 that were expressed either normally or in an
elevated fashion on NK cells of viremic patients were responsible
for a greater receptor-specific inhibition of cytolytic function. It
should be pointed out that of the iNKRs that we examined, only
NKG2A was down-regulated, and this down-regulation was asso-
ciated with the least inhibitory function in the redirected killing
assay. The reason for this selective decrease in expression under
conditions in which other iNKRs are up-regulated is presently
unclear.
In a similar manner, the functional capabilities of the NCRs as
determined in the redirected killing assay reflected the phenotypic
abnormalities that were observed. In this regard, NK cytolytic
function mediated through NKp46, NKp30, and NKp44, whose
expression was markedly decreased among viremic individuals, was
strongly impaired. Furthermore, NK cytolytic function mediated
through NKG2D, whose expression was not significantly dimin-
ished in viremic patients, was only modestly impaired. As with the
iNKRs, NK functional capability related to NCRs and NKG2D was
normal in HIV-infected individuals who were rendered aviremic
while receiving HAART.
It has been reported that levels of TGF- are elevated in the
plasma of HIV-infected individuals (26), and TGF- has recently
been shown to down-regulate NKp30 and NKG2D in vitro (27).
Thus, we investigated whether there were any differences in the
capability of NK cells from viremic versus aviremic HIV-infected
individuals versus healthy donors to secrete TGF- in culture after
6 h (freshly isolated) and 6 days in culture with rIL-2 (activated). We
did not find any differences in secretion of TGF- in the superna-
tant of NK cultures among the three cohorts of subjects. Thus, it is
unlikely that the decrement in NKp30 expression that was observed
in HIV-infected patients is attributable to a TGF--dependent
autocrine mechanism. However, it is possible that the decrement
may be caused by high levels of TGF- that are produced by cells
other than NK cells.
We also demonstrated that direct infection of NK cells by HIV-1
was not responsible for the abnormal expression and activity of
iNKR, NCRs, or NKG2D, because freshly isolated and activated
NK cells from HIV-1 positive donors did not harbor HIV. Finally,
we demonstrated that the impaired spontaneous cytolytic function
of freshly isolated NK cells among viremic individuals was associ-
ated with an impaired secretion of INF- as has been reported with
cloned NK cells (28). Only since the availability of HAART, which
has been shown to successfully suppress plasma viremia to below
detectable levels in a significant proportion of HIV-infected pa-
tients, have investigators been able to carefully examine the precise
effects of viremia on various immune cell functions (29, 30). In this
regard, in comparisons of viremic and aviremic HIV-infected
individuals, we have recently demonstrated that viremia is associ-
ated with an abnormal pattern of gene expression in resting CD4
T cells (31) as well as abnormal phenotype and functional capability
of B cells (32, 33). This study demonstrates striking differences in
the phenotype and function of NK cells in viremic individuals.
Longitudinal studies of viremic patients are necessary to evaluate
recovery time of NK cell function in HIV-1-infected viremic donors
who subsequently become aviremic on HAART. The dichotomy of
expression of KIRs, NKG2A, and NCRs, together with the func-
tional correlates, provides insight into the mechanisms of impair-
ment of NK function in viremic HIV-infected patients and serves
as a potentially important model for the relevance of the physiologic
balance of NK receptor expression in the integrity of the innate
immune system.
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